EcoDrugPlus

Dna Topoisomerase I

Ensembl ID : ENSFCAG00000009029
Gene Symbol: TOP1
5 Cross references
273 Possible Orthologues:

Dna Topoisomerase Ii Alpha

Ensembl ID : ENSFCAG00000009642
Gene Symbol: TOP2A
5 Cross references
206 Possible Orthologues:

Dna Topoisomerase Ii Beta

Ensembl ID : ENSFCAG00000031328
Gene Symbol: TOP2B
5 Cross references
210 Possible Orthologues:

Emap Like 4

Ensembl ID : ENSFCAG00000015377
Gene Symbol: EML4
5 Cross references
214 Possible Orthologues:

Eph Receptor A2

Ensembl ID : ENSFCAG00000010170
Gene Symbol: EPHA2
3 Cross references
124 Possible Orthologues:

Eph Receptor A3

Ensembl ID : ENSFCAG00000024008
Gene Symbol: EPHA3
5 Cross references
216 Possible Orthologues:

Eph Receptor B4

Ensembl ID : ENSFCAG00000006852
Gene Symbol: EPHB4
5 Cross references
168 Possible Orthologues:

F2r Like Thrombin Or Trypsin Receptor 3

Ensembl ID : ENSFCAG00000001577
Gene Symbol: F2RL3
5 Cross references
193 Possible Orthologues:

Fau Ubiquitin Like And Ribosomal Protein S30 Fusion

Ensembl ID : ENSFCAG00000001442
Gene Symbol: FAU
5 Cross references
229 Possible Orthologues:

Fkbp Prolyl Isomerase 1a

Ensembl ID : ENSFCAG00000039926
Gene Symbol: FKBP1A
4 Cross references
186 Possible Orthologues:

Fxyd Domain Containing Ion Transport Regulator 2

Ensembl ID : ENSFCAG00000034959
Gene Symbol: FXYD2
5 Cross references
71 Possible Orthologues:

Fyn Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSFCAG00000023350
Gene Symbol: FYN
5 Cross references
264 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).